RADNOR, Pa., Sept. 27, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, has initiated a Phase 1B/2 clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of enoxaparin (Lovenox®), a low molecular weight heparin (LMWH). PMX-60056 is a small-molecule designed to modulate coagulation and mitigate bleeding in certain interventional cardiology procedures and emergency situations. PMX-60056 is also currently in a Phase 2 clinical trial in patients undergoing Percutaneous Coronary Intervention (PCI).
